Boothwyn Pharmacy
Contact pharmacy ↗ Request an introduction ↗Patient access unconfirmed
Qualifying compounding service unconfirmed · Retained for review in the company index.
Peptide and GLP-1 compounding have not been confirmed for this location.
Can this pharmacy serve my state?
Choose your state and service to check shipping and license evidence.
We have not confirmed a shipping policy for this selection. Ask the pharmacy about your medication and destination
We have not matched a state-board record for this state
“Not confirmed” is a gap in our review, not a finding that the pharmacy is unlicensed or cannot ship.
Shipping scope and restrictions
No current enumerated pharmacy shipping or reported-license state list was verified.
Confirm your exact medication and delivery address with the pharmacy. A license record does not confirm that every preparation can be shipped.
License records checked (3)
Checked November 3, 2026. These records are specific to this location. General pharmacy, sterile-compounding and outsourcing permits can have different scopes.
- OH · #022534950Active
Expires Mar 31, 2027
State board record ↗ - CT · #PCN.0002758ACTIVE
Expires Aug 31, 2027
State board record ↗ - OK · #99-8077License in Good Standing
Expires Nov 30, 2026
State board record ↗
Compare all states
Shipping follows the service selected above. License status is checked separately.
No shipping destination is confirmed in this review.
State-board license record matched for Connecticut, Ohio and Oklahoma.
| State | Reported shipping | License status |
|---|
Facility type and oversight
- Facility type
- Not yet confirmedFacility classification awaits confirmation
- Accreditation
- Not yet checkedCurrent scope and status await verification.
Check the facility name, address, scope and expiration with the issuer.
Regulatory history
Earlier PW review recorded “Warning Letter 2026-01-16”. Consult the regulator for the current record.
Compounding specialties
- GLP-1 compounding
- Not confirmed in this review
- Other peptide compounding
- Not confirmed in this review
FDA's January 2026 warning identifies prior sterile semaglutide/tirzepatide compounding and a production pause. Notice of an intention to resume does not establish current resumed production. No current primary peptide offer was verified.
Organization and scale
- Company or brand
- Boothwyn Pharmacy
- Founded
- Not confirmed
- Company-reported scale
- Not confirmed
Where the information came from
- Facility review evidence ↗November 3, 2026
- Facility identification ↗
- OH licensing authority ↗Facility license · checked November 3, 2026
- CT licensing authority ↗Facility license · checked November 3, 2026
- OK licensing authority ↗Facility license · checked November 3, 2026
Sources and methodology
Services and shipping statements are attributed to their sources; state-board license records are checked separately. Missing information stays unconfirmed. Explore the editorial guide or company research index. Nearby distances use approximate city and ZIP centers from GeoNames under CC BY 4.0. Confirm pickup and current availability directly with the pharmacy.